Parabilis director-linked fund buys 17,500 PBLS shares
Parabilis Medicines director Alan Sebulsky reported indirect open-market purchases of Parabilis Medicines, Inc. common stock through Apothecary Capital LLC.
Rhea-AI Filing Summary
Parabilis Medicines director Alan Sebulsky reported indirect open-market purchases of Parabilis Medicines, Inc. common stock through Apothecary Capital LLC. Across three transactions on June 12 and June 15, Apothecary Capital bought a total of 17,500 shares at weighted average prices reported as $27.6696, $25.9978 and $27.0963 per share. Following the most recent transaction, Apothecary Capital holds 30,000 shares. Footnotes state Sebulsky is the managing member of Apothecary Capital and may share voting and investment power but disclaims beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 17,500 shares
Net Buy
3 txns
Insider
SEBULSKY ALAN
Role
Director
Bought
17,500 shs ($474K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $25.9978 | $130K |
| Purchase | Common Stock | 4,065 | $27.0963 | $110K |
| Purchase | Common Stock | 8,435 | $27.6696 | $233K |
Holdings After Transaction:
Common Stock — 30,000 shares (Indirect, By Apothecary Capital LLC)
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.16 to $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1, 3 and 4 to this Form 4.
- F2. Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.25, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.00 to $27.20, inclusive.
Key Figures
Total shares purchased: 17,500 shares
Weighted average price 1: $27.6696 per share
Weighted average price 2: $25.9978 per share
+2 more
5 metrics
Total shares purchased
17,500 shares
Open-market common stock purchases by Apothecary Capital LLC
Weighted average price 1
$27.6696 per share
June 12, 2026 common stock purchase
Weighted average price 2
$25.9978 per share
June 15, 2026 common stock purchase
Weighted average price 3
$27.0963 per share
June 15, 2026 common stock purchase
Shares held after latest trade
30,000 shares
Apothecary Capital LLC indirect holdings post-transaction
Key Terms
open-market purchase, weighted average price, beneficial ownership, Section 16 of the Securities Exchange Act of 1934, +1 more
5 terms
open-market purchase financial
"transaction_action is described as an open-market purchase of common stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
voting, investment and dispositive power financial
"may be deemed to share voting, investment and dispositive power with respect to the securities"
AI-generated analysis. How Rhea-AI works. Not financial advice.
